Member Info for pomander

Bignose- has been range bound for some time and volumes very low so I am not reading too much into current SP action. When (if) market realisation of commercial propsects for Fortacin arises, SP will react accordingly and at current mkt cap if positive I would expect multiple & longer term holders. EU launch is massive compared to UK,. Profit warning will be interesting �m plus Venturex versus amortisiation of invetsmenet in Plethora- at elast some income to offeset for a change ! But what is poistion re DBC ? Write down ? Hopefully MW attarcts some interest.

I see bIllings have made a tender offer to shareholders at 4.25p - RP's loss but JM will have doubled his money on that one !

Prof- the UK price drop is just to clear stock that will go out of date in march 2018. It is not an indication of the future price as that will be entriely Recordati's decision, including for the UK. The article is incorrect in that the 5ml can was reduced from �59.99 to �20, but as written might lead punters to beleive they are getting a bigger discount! UK launch was always going to be low key, as was just a technical launch- I guess any publicity is goods publicity.

Apologists for Jim Mellon's Regent Pacific, which thanks to the all share takeover of Plethora (PLE) has many British investors, have reacted fiercely to my article last week on how it was slashing Fortacin prices by 80%. This prompts me into further work and the alarm bells really are now ringing loudly. One supporter who seems well briefed by the company, says that it is only the price of 5mg Fortacin that is being slashed from �99.99 to �19.99 in the UK, prices of the 20 mg spray for Premature Ejaculation are being held. The price cut is blamed on the need to clear stock approaching its expiry date. That, if true, is damning, implying that folks just do not want to buy the product in anything like the volumes anticipated. The defender of Mellon then goes onto say that the UK is not a critical market, the real potential is in Europe and Asia and that the UK was only a "soft launch" anyway. We shall see. For what it is worth if you check the statements made by Regent Pacific, notably in the run up to the April bailout placing, you will see no reference to a soft launch. It is all guns blazing for a major UK launch - which started in November 2016 - ahead of a European launch in late 2017. Even now the company is not claiming officially that the UK was a soft launch although I note that in the six months to June 30 2017 revenues from Fortacin were precisely nil. But we do know that European launches have been postponed to early 2018. Why? Is it perhaps because the UK has been such a damp squib? And that brings us to the financials. The first half of calendar 2017 was - as per the need for a profits warning - dire. When the results came out on August 25 we were reassured that the company had a strong enough balance sheet which was " Debt free, with over US$6.22 million in cash, listed and unlisted securities" That was no doubt helped by a c$4 million fund raise and by selling all its shares in Condor Gold ( at a loss) for $2.51 million. But hang on.... the devil is in the detail for which you need to go beyond the press release to the actual interim report. Cash was only c$1.5 million. Much of that $6.6 million ( c$2.5 million) was the carrying value of Regent's interest in another Mellon dog, Diabetic Boot, which as noted, most recently HERE, is worthless. Meanwhile current liabilities stood at $3.7 million. Ouch. And as a bonus cashburn in H1 was $3.7 million and there is no reason why that would change. So is Regent ****ed? Not entirely. Firstly there is a 22% stake in a wildly overpromoted by fairly illiquid ASX mining stock Venturex. At the half year Regent held c22% of this company which after a major ramp is now worth c$10 million. But selling is not easy. T^he other day Regent managed to sell c$76,000 worth of stock. I guess it might take some time to offload the rest but every little helps. Then there is the European rollout. On 25 August we were told: Post the interim reporting p

Bunion- the longevity of the man is hard to fathom, he shoots from the hip more often than not, and not having teh first clue about what he is talking about. If he were such a guru, don't think he would be doing this for a living. Could'nt even run a Pizzza Restaurant, no wonder JM culled him and his failing tips.com very quickly - hence the bitterness. He is an intergal part of the Cesspit bit of the AIM market to which he refers.

PXS Can't see where you picked the date up from, but don't have time to look - but sure you are correct. Also its the 5m (12 doses) can that has been reduced from �59.99 not the 6.5m can (20 doses) from �99.99. Don't feel it is anyuthing to get over exercised by - no marketing effort in UK and all publicity is good.

Thks Dougie - very interesting, probably around the price point most of us intuitively believed was in the right ballpark. Wonder how this fits with Recordati launch and the overall strategy generally, as would seem a starnge move just to try and generate a few extra UK sales unless another plan in play.

Try PE - wrong condition

Is that what Anne Summers is selling these days - I must be out of touch. In all seriousness, over the longer term this is a potentially siginificant development and might increase the attractiveness of Plethora as a target.

Interesting, a very sensible and pragmatic approach - although I will not be tweeking my spredsheets just yet , but a good sign of what maybe to come.( oh dear)

Alq - ''In the absence of any other potential revenue stream'' - if that's your view on Fortacin, then we are not going to have a sensible conversation and behuge is getting blisters on his thumb recommending you, so best to move on and agree to differ.

Alq, I think this is very well trodden old ground. I don�t follow the logic of launching a Ferrari on the basis of relying upon historical data for a Ford Escort. - no offence to Ford Escort drivers intended. RP has made it very clear that the projections produced by Recordati were massively stronger than the guidance provided in their presentations, and I can understand there being sound corporate reasons for that. You also assume that every license deal, within certain parameters, is perfectly priced as to the future commercial prospects. I suspect there are as many bad deals in pharma as with any other sector, indeed probably more. You also remain fixated by just the EU market for some reason. There may not be data available in the precise clinical format required by technical consultants such as you, but like most advisers and consultants these days; they are more concerned about covering their own tails. I suspect that if you buy into the commercial opportunity that Fortacin presents by being the first ever approved treatment for PE, which in my book catapults it to �best in class� even without its other clinical advantages over a bunch of dodgy marketing driven OTC products, that the data available on the PE market is more than adequate. I agree 3x sales was too rich, and said so, as they are just projections at this stage but big bucks are paid for licenses with only potential sales on the table. The bottom line remains, you don�t view Fortacin as having any commercial potential of note whilst others do.

Dougie - purely illustrative numbers. If you beleive there in the blockbuster potential which has been banded about ($1 billion + annual sales), not uncommon for a pharma to be valued a 3x sales. I think this is too rich, but you pays your money and takes your choice, I suspect the middle ground is more likeley if a suitor buys into thecommercial potential. There has of course been any number of dud and over paid aquisitions in the pharma sector over the years. Let's just hope Alq is not advising them, unless well into beer time !

richatthecroft I use the term cure loosely and are you are correct in pulling me up, although developin a drug that will arrest the symptons of the disease remains a very tall order, and sadly one that the statistcal evidence shows the chances of success are slim. In regards to Ridinilazole, I am not doubting it potential as drug on the clinical side, and it many ways that highlights te problem facing Summ. The challenge it faces is on the commercial side as bi-pharma currently has little or no interest in developing or selling antibiotic drugs. This is widely known. The profit margins and likeley government intervention simply do not make new antibiotics commercially compelling to develop and sell. With the clinical benefits that you allude to, surely you must also be question why big-pharma or a licence deal or the funding needed to take it to market has not been raised. Having said that Summit cannot take a drug to market, its needs a staregic partner with deep pockets to do that, but unable to attract that partner. You see teh same type of scenario when there is an outsbreak of a new dieasse or strain occur and for which a drug company might have an indication for.Its share price often rockets initially, until the commercial reality and the effect of government intervention becomes a reality. Its sad as it means billions are wasted on finding a cure for conditions such as baldness . Do you own GSK or Sanofi by any chance ?

I suspect offer would be for Plethora, unless acquirer wanted the HK listing. In which case the RP share price would adjust accordingly to the offer price as it would effectively be a cash shell

Bignose- I think the technical term is slippage, but these guys seem to be fairly adept at bouncing back up , no matter how big the slippage might be. Perhaps that is down to the product potential. Inspite of of, not because of syndrome. I agree with your sentiments about JM's personal motivation and I thinbk he would like to climb the ST Rich List sooner rather than latter. A chunky sale would achieve that objective taher nicely and I think rather better than say 10 years of dividends. Turning $30m into $300m or whatever the number might be is a good story. It would also catapult RP into being viewed a serious player amongst the HK investor community. One also has to always keep in mind that future sales projections , apart from the obvious risk that they are simply wrong also carry the risk of new entrants emerging given such a long time period. I still wonder if RP are holding off signing up futher licenses until after the EU launch so as not to compromise any potential interest. Given the problems running RP at the moment, even a website,! - I am sure how RP would even manage a global rollout.

All pharma CEO' s worth the title passionately and genuinely beleive that they have a shot at finding a cure to any number of diseases. Displaying this passion is critical in both raising awareness of the disease, and in raising funding to find the cure. Attending conferences is just one of a number of ways to achieve these ends. Unfortunately only about 8% of CEO' succeed in their objectives and DMD is a particularly difficult desease to find a cure for as is evidneced by the billions that have laready been spent on doing. That of course does not mean a cure will not eventually be found, just that the historical probabilities of doing so are not favourable. In anwer to your question therefore, I beleive attending conferences is not correlated to the BOD having a very good idea of the probable success.

My belief is, and always has been, that the objective is to sell Plethora at the right time. RP is in the buisness of investing into and exiting bio pharma companies. Running thoise companies on a dya to day basis is not the buisness model. The sale of Plethora would provide the ncessary funds to begin to build a portfolio of bio pharma investments. RP has done nothing in the way of fund raising to make further investments, so when and where are those funds going to come from in order for it to pursue its vision of becoming HK's leading healthcare and life sciences investment enterprise? Certainly not the DBC !

Customary top sniffing - I thought you sonded more upbeat. Volumes back down again,

Not me , I would rather invest the $3,500 in RP shares